KJT
Shetal Vyas is a seasoned leader in the life sciences sector, currently serving as an Advisory Board Member for Aquent and as an Independent Board Director for KJT. With a proven track record at Ferring Pharmaceuticals, Shetal launched the first-ever gene therapy for bladder cancer and held multiple vice president roles focused on operations and business unit leadership. Previous experience includes significant marketing leadership positions at Pentec Health and Vermillion, Inc., where Shetal drove substantial revenue growth and market development. An educational background includes advanced management programs at Harvard Business School and an MBA in Marketing from Saint Joseph's University.
This person is not in the org chart
This person is not in any teams
KJT
As a strategic partner to life sciences companies throughout the product lifecycle, our goal is profound: positively impact your business to help improve healthcare globally. We tailor our evidence generation and communication solutions to do just that. Let’s take research further, together.